Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Lytix Biopharma A/S

Headquarters: Tromso, Norway
Year Founded: 2003
Status: Public
Industry Sector: HealthTechnology
CEO: Øystein Rekdal, PhD
Number Of Employees: 6
Enterprise Value: $16,783,856
PE Ratio: -2.59
Exchange/Ticker 1: OSE:LYTIX
Exchange/Ticker 2: N/A
Latest Market Cap: $32,167,798

BioCentury | Jun 7, 2024
Management Tracks

Boston Pharma names Margaret Koziel CMO

Plus: Phillip Dennis joins I-Mab as CMO, and an update from Exscientia
BioCentury | May 7, 2021
Finance

The Nordic Track for financing biotechs

Early access to the Scandinavian public markets can create problems for finding growth capital
BioCentury | Aug 11, 2020
Deals

After Verrica deal in dermatological cancer, Lytix looks ahead to next-generation oncology product

Norwegian biotech Lytix has found a partner for its lead program in dermatological cancers, affording it the opportunity to continue that product’s development in additional indications while
BioCentury | Aug 20, 2018
Company News

Management tracks: Athenex, Intra-Cellular

BioCentury | Jun 13, 2018
Company News

Management tracks: Salk Institute, Galectin

BioCentury | Oct 24, 2017
Company News

Management tracks: Five Prime, CytoSen

BioCentury | Oct 12, 2015
Clinical News

Oncopore: Phase I data

BioCentury | Feb 23, 2015
Emerging Company Profile

Eyeing new antibiotics

Why SinSa's peptide antimicrobials could have low risk of resistance
Items per page:
1 - 10 of 23